Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

NCT00582673 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: AFQ056
DRUG: Placebo

Sponsor

Novartis